Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 10/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.56 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15989014 | 0.96 | P2RY2 (0.56) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL19546708 | 0.93 | P2RY6 (0.59) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL19862754 | 0.93 | P2RY6 (0.59) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL24043084 | 0.93 | P2RY6 (0.59) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL18126746 | 0.93 | P2RY6 (0.59) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL15989035 | 0.92 | P2RY6 (0.52) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL22455604 | 0.92 | P2RY6 (0.52) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL8630942 | 0.91 | SLC28A1 (0.55) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL15989021 | 0.90 | P2RY6 (0.53) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL25955354 | 0.90 | P2RY2 (0.60) | P2RY2P2RY6P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896688-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage | SIRNA THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160068837-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | SIRNA THERAPEUTICS, INC. (US) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068837-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | NSUN2, AGO2, NSUN3 | P2RY2 3078/4885P2RY6 3524/4885P2RY4 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.